|
|
|
|
|
|
by aaavl2821
2659 days ago
|
|
|
That links a 404 for me but I'd want to investigate the methodologies. The r&d numbers for the industry seem low as do the revenues, I don't know what sample of companies they used Also don't know what criteria Bentley used to determine how much NIH research contributed to new drugs This report provides another perspective and highlights the role of industry http://www.hbmpartners.com/media/docs/industry-reports/Analy... |
|
|
The HBM partner report seems to somewhat confirm some of the findings in the report I linked and quoted:
- 50% of drugs come from outside “Big Pharma”
- Less than 50% drugs developed in-house (mostly coming from licensing and acquisition)
Also:
- 58% approved drugs are orphan drugs.
Orphan drugs may mean government incentives, funding, public policy.